<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00871949</url>
  </required_header>
  <id_info>
    <org_study_id>B1171001</org_study_id>
    <nct_id>NCT00871949</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults</brief_title>
  <official_title>A Phase 1 Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PNU-100480 (PF-02341272) After First Time Administration Of Ascending Oral Doses To Healthy Adult Subjects Under Fed And Fasted Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sequella, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sequella, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of
      PNU-100480 (PF-02341272) after a single dose in healthy adult volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of safety and tolerability of escalating single oral doses of PNU-100480.</measure>
    <time_frame>Daily, Days 1-3 or 4, and 7-14 days after dosing.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize pharmacokinetics of single oral doses PNU-100480.</measure>
    <time_frame>Predose; multiple timepoints postdose on Day 1, and up to 72 hours postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the effect of food on the pharmacokinetics of a single oral dose of PNU-100480.</measure>
    <time_frame>Predose; multiple timepoints postdose on Day 1, and up to 72 hours postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the bactericidal activity in blood of orally administered PNU-100480 against intracellular Mycobacterium tuberculosis in relation to blood concentrations of PNU-100480 (and its metabolites) (some periods only)</measure>
    <time_frame>Predose and timpoints up to 24 hours post dose on Day 1 (only in some periods)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1, Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1- Placebo Period 2- 100 mg Period 3- 300 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1- 35 mg Period 2- Placebo Period 3- 300 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1- 35 mg Period 2- 100 mg Period 3- Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1- Placebo Period 2- 1000 mg Period 3- 1500 mg Period 4- 600 mg (Fed conditions)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1- 600 mg Period 2- Placebo Period 3- 1500 mg Period 4- 600 mg (Fed conditions)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1- 600 mg Period 2- 1000 mg Period 3- Placebo Period 4- 600 mg (Fed conditions)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PNU-100480</intervention_name>
    <description>100 mg oral suspension given once</description>
    <arm_group_label>Cohort 1, Sequence 1</arm_group_label>
    <other_name>Period 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PNU-100480</intervention_name>
    <description>300 mg oral suspension given once</description>
    <arm_group_label>Cohort 1, Sequence 1</arm_group_label>
    <other_name>Period 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo to match oral suspension given once</description>
    <arm_group_label>Cohort 1, Sequence 1</arm_group_label>
    <other_name>Period 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PNU-100480</intervention_name>
    <description>300 mg oral suspension given once</description>
    <arm_group_label>Cohort 1, Sequence 2</arm_group_label>
    <other_name>Period 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PNU-100480</intervention_name>
    <description>35 mg oral suspension given once</description>
    <arm_group_label>Cohort 1, Sequence 2</arm_group_label>
    <other_name>Period 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo to match oral suspension given once</description>
    <arm_group_label>Cohort 1, Sequence 2</arm_group_label>
    <other_name>Period 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PNU-100480</intervention_name>
    <description>100 mg oral suspension given once</description>
    <arm_group_label>Cohort 1, Sequence 3</arm_group_label>
    <other_name>Period 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PNU-100480</intervention_name>
    <description>35 mg oral suspension given once</description>
    <arm_group_label>Cohort 1, Sequence 3</arm_group_label>
    <other_name>Period 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo to match oral suspension given once</description>
    <arm_group_label>Cohort 1, Sequence 3</arm_group_label>
    <other_name>Period 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PNU-100480</intervention_name>
    <description>1000 mg oral suspension given once</description>
    <arm_group_label>Cohort 2, Sequence 1</arm_group_label>
    <other_name>Period 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PNU-100480</intervention_name>
    <description>1500 mg oral suspension given once</description>
    <arm_group_label>Cohort 2, Sequence 1</arm_group_label>
    <other_name>Period 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PNU-100480</intervention_name>
    <description>Fed conditions, 600 mg oral suspension given once</description>
    <arm_group_label>Cohort 2, Sequence 1</arm_group_label>
    <other_name>Period 4 (Fed)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo to match oral suspension given once</description>
    <arm_group_label>Cohort 2, Sequence 1</arm_group_label>
    <other_name>Period 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PNU-100480</intervention_name>
    <description>1500 mg oral suspension given once</description>
    <arm_group_label>Cohort 2, Sequence 2</arm_group_label>
    <other_name>Period 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PNU-100480</intervention_name>
    <description>600 mg oral suspension given once</description>
    <arm_group_label>Cohort 2, Sequence 2</arm_group_label>
    <other_name>Period 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PNU-100480</intervention_name>
    <description>Fed conditions, 600 mg oral suspension given once</description>
    <arm_group_label>Cohort 2, Sequence 2</arm_group_label>
    <other_name>Period 4 (Fed)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo to match oral suspension given once</description>
    <arm_group_label>Cohort 2, Sequence 2</arm_group_label>
    <other_name>Period 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PNU-100480</intervention_name>
    <description>1000 mg oral suspension given once</description>
    <arm_group_label>Cohort 2, Sequence 3</arm_group_label>
    <other_name>Period 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PNU-100480</intervention_name>
    <description>600 mg oral suspension given once</description>
    <arm_group_label>Cohort 2, Sequence 3</arm_group_label>
    <other_name>Period 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PNU-100480</intervention_name>
    <description>Fed conditions, 600 mg oral suspension given once</description>
    <arm_group_label>Cohort 2, Sequence 3</arm_group_label>
    <other_name>Period 4 (Fed)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo to match oral suspension given once</description>
    <arm_group_label>Cohort 2, Sequence 3</arm_group_label>
    <other_name>Period 3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult volunteers willing and able to be confined to the Clinical Research Unit
             and comply with study schedule.

          -  Women of non-childbearing potential only.

        Exclusion Criteria:

          -  History of hypersensitivity to, or intolerance of, linezolid.

          -  Antibiotic treatment within 14 days prior to dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Beth Ferstenberg, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Sequella, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1171001&amp;StudyName=Safety%2C%20Tolerability%20And%20Pharmacokinetics%20Study%20Of%20Single%20Doses%20Of%20PNU-100480%20In%20Healthy%20Adults</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2009</study_first_submitted>
  <study_first_submitted_qc>March 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2009</study_first_posted>
  <last_update_submitted>August 26, 2013</last_update_submitted>
  <last_update_submitted_qc>August 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety tolerability pharmacokinetics PK first in human FIH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxazolidinones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

